Could tocilizumab reduce COVID-19 symptoms for blood cancer patients?

Written by Rachel Jenkins, Future Science Group

The report, recently published in Blood Advances, demonstrates that the immunosuppressant, tocilizumab, could be an effective therapy against COVID-19 symptoms for patients with multiple myeloma and other blood cancers. Additional findings from the report suggest that blood cancer patients may have atypical COVID-19 symptoms. “Our patients with hematologic malignancies are immunosuppressed, which may put them at higher risk for novel coronavirus infection. What are the characteristics of COVID-19 in patients with blood cancers? What is the optimal treatment approach? Everything is unknown, and that was the motivation for this study,” explained Changcheng Zheng (University of Science and Technology of China,...

To view this content, please register now for access

It's completely free